Navigation Links
Mayo researchers find biomarkers for personalizing radiation cancer treatment

ROCHESTER, Minn. -- Mayo Clinic researchers have discovered biomarkers that could lead to personalized radiation treatments for cancer patients. The findings appear today online in the journal Genome Research.

"Overcoming resistance to radiation therapy would make treatment more effective for some individuals," says Liewei Wang, M.D., Ph.D., Mayo Clinic genomic researcher and senior author of the study. "Our findings may make it possible to one day develop novel therapies aimed at selected subgroups of cancer patients."

Roughly half of all cancer patients undergo radiation therapy, but the response -- the impact on the patient and the cancer -- can vary greatly. It's thought that genetic variants -- differences in personal genomes -- may be the reason in most cases. Dr. Wang and her team investigated 277 different human lymphoblastoid cell lines in an attempt to learn more about why some patients respond differently.

As part of their genome-wide association study, they integrated data on gene expression, cell toxicity outcomes, and 1.3 million single nucleotide polymorphisms (SNPs), the brief sections of genetic code representing variants. They then narrowed the field and validated likely biomarkers in three cell lines to confirm radiation response. In the end, they identified five genes in which gene expression related directly to radiation response.


Contact: Robert Nellis
Mayo Clinic

Page: 1

Related medicine news :

1. Insurance, Race and Poverty Affect Cancer Care, Researchers Report
2. Johns Hopkins researchers turn off severe food allergies in mice
3. UTHealth researchers awarded $15 million for teen pregnancy prevention
4. Researchers discover genetic changes that make some forms of brain cancer more aggressive
5. Researchers find no difference in drugs for macular degeneration
6. Researchers advance biosynthesis of potent anti-cancer drug Taxol
7. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
8. Researchers at the University of Granada associate trigger points with shoulder injury
9. Researchers to study effects of Mass. health reform
10. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
11. Researchers use CT to predict heart disease
Post Your Comments:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology: